US envoy describes Trump tying aid to Biden investigation
The acting ambassador to Ukraine has stunned a congressional committee with evidence claiming that Trump directly tried to use offers of military aid and a summit meeting to make Ukraine’s president begin investigations designed to undermine his opponents. Bill Taylor told the committee holding impeachment hearings that Trump had made it clear that aid and the meeting would be dependent on investigations into Hunter Biden, the son of former US vice president Joe Biden, and into the conspiracy theory that Ukraine was involved in clandestinely helping the Democrats during the 2016 presidential election.
Universities failing to address racism
Nearly a quarter of ethnic minority students at UK universities have faced racism since starting their courses, and institutions are in denial over the scale of the problem, according to a report by the Equality and Human Rights Commission. The report found that eight per cent of students surveyed experienced racist harassment in the first half of the last academic year, equating to around 180,000 students.
Johnson’s Brexit timetable rejected
MPs have rejected Boris Johnson’s attempt to force through his Brexit deal within three days, leaving the Prime Minister facing the prospect of missing his 31 October deadline for leaving the EU and under pressure to call an election. Parliament passed the second reading of the withdrawal bill but voted down a programming motion which would have limited time to scrutinise and amend the terms for exiting the EU put forward by the government.
Police to interview US suspect in Harry Dunn crash
Police are to interview under caution the wife of a US diplomat suspected of involvement in the fatal crash which killed 19-year-old motorcyclist Harry Dunn. Anne Sacoolas left the UK following the crash and claimed diplomatic immunity, despite initially telling police she would cooperate with inquiries.
First trials find drug that could slow down Alzheimers
A drug that could slow the onset of Alzheimers disease has produced successful trial results for the first time, opening up treatment options for the most common cause of dementia. Makers Biogen claimed that aducanumab could slow the disease by as much as 25 per cent in those treated early, but some experts urged caution saying that further tests and rulings from US regulators were required to assess its efficacy.